CN Patent
CN113444105A — 一种Relugolix的制备方法
Assigned to Nanjing Hairun Pharmaceutical Co ltd · Expires 2021-09-28 · 5y expired
What this patent protects
本发明属于药物制备领域,涉及具有促性腺素释放激素(GnRH)拮抗作用的Relugolix或其盐的制备方法,与原研提供的Relugolix的制备方法相比,该方法将含苯胺结构的杂质及RS‑1等进行清除,合成工艺简单,反应收率高,避免氢化,更容易实现工业化生产,成品中含苯胺类警示结构杂质RS‑2未检出,且RS‑1及RS‑3均控制在0.01%以下。
USPTO Abstract
本发明属于药物制备领域,涉及具有促性腺素释放激素(GnRH)拮抗作用的Relugolix或其盐的制备方法,与原研提供的Relugolix的制备方法相比,该方法将含苯胺结构的杂质及RS‑1等进行清除,合成工艺简单,反应收率高,避免氢化,更容易实现工业化生产,成品中含苯胺类警示结构杂质RS‑2未检出,且RS‑1及RS‑3均控制在0.01%以下。
Drugs covered by this patent
- Orgovyx (relugolix) · MYOVANT SCIENCES
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.